FindTrial
Sign In

An Open-Label, Single-Centre Behavioural study to Evaluate the Impact of Shilajit Supplements in increasing the Quality of Life in Men

A Prospective, Single-arm, Open-Label, Single-Centre Behavioural Study to Evaluate the Impact of Shilajit Supplements in increasing Quality of Life in Men - NIL

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/02/062518
Enrollment
50
Registered
2024-02-12
Start date
Unknown
Completion date
Unknown
Last updated
2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Azuretale Inc
Lead Sponsor
Azuretale Private Limited
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: 1.Age Range: Adult males aged between 30 and 60 years. 2.Health Status: Individuals experiencing reduced vitality or cognitive issues but generally in good health. 3.Consent:Willing to provide informed consent and adhere to study protocol. 4.Availability: Able to participate in all scheduled visits and assessments during the 30- day study period.

Exclusion criteria

Exclusion criteria: 1.Chronic Diseases: Individuals with severe chronic diseases, especially uncontrolled diabetes, cardiovascular diseases, or severe neurological disorders. 2.Current Medication: Use of cognitive enhancers, testosterone supplements, or other medications that might interfere with the study outcomes. 3.Substance Abuse: History of alcohol or substance abuse within the last six months. 4.Psychiatric Conditions: Significant psychiatric disorders that could affect compliance or skew results. 5.Other Clinical Trials: Participation in another clinical trial within the last three months.

Design outcomes

Primary

MeasureTime frame
1.Quality of Life improvement 2.Improvement in the testosterone levels. 3.Cognitive Function enhancement.Timepoint: Day 0, 10, 20 and 30—

Secondary

MeasureTime frame
1.Improvement in Sleep Patterns. 2.Assessment of General Immune functions. 3.SafetyTimepoint: Day 0, 10, 20 and 30—

Countries

India

Contacts

Public ContactMs.Sathyavathi LM

Azuretale Private Limited

vijaykimtata.vk@gmail.com919816333352

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026